Pharmacological Approach for Prevention of Bleomycin-Induced Lung Injury

Mohammad Ayoubifar; Farshad Abedi; Mohammad  Moeini Nodeh; Omid Arasteh

doi:10.18502/jpc.v11i1.12638

Mohammad Ayoubifar School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Farshad Abedi Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Moeini Nodeh Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, Mashhad University of Medical Sciences Mashhad, Iran.
Omid Arasteh Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

DOI: https://doi.org/10.18502/jpc.v11i1.12638

Keywords: Bleomycin; Lung Injury; Antioxidant; Anti-inflammatory

Abstract

Bleomycin is a chemotherapeutic medication commonly use in the treatment of Hodgkin's disease and germ cell tumors. Pulmonary fibrosis is major and dose limiting adverse effect of the drug. There is not currently any equal alternative approach or a medical agent for prevention of its pulmonary injury. We searched scientific databases in order to find investigational pharmacologic medicines in prevention of bleomycin-induced lung toxicity (BILI). Results revealed that some anti-inflammatory and antioxidant preparations such as statins, N-acetylcysteine (NAC), supplements (vitamin D₃, L-arginine, selenium), and renin-angiotensin-aldosterone system (RASS) inhibitors might be effective in preclinical models of pulmonary toxicity mediated by bleomycin. However, we still need more in vivo studies and large human randomized clinical trials to confirm their benefits.